Recent years have seen substantial advances in lung cancer management, with therapeutic options expanding rapidly through the integration of targeted therapies, immunotherapies, antibody-drug conjugates, and novel, immune-engaging agents. Although outcomes have improved for selected patients with non-small cell lung ca...
N. Florez, S. Patel, R. Salgia et al.· Cancer· 0 citations
Lung cancer remains the leading cause of cancer-related death globally, despite significant advances in diagnosis and treatment. Single biomarker approaches used clinically, such as programmed death ligand-1 (PD-L1) expression levels, have limited capacity for predicting treatment response. Multimodal data analysis usi...
T. Chakrabarti, A. Mansour, Xi-Wei Wu et al.· Cancers· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.